Consolidated Statement of Comprehensive Income Ono Pharmaceutical Co., Ltd. and Consolidated Subsidiaries

	Millions of yen				Thousands of US\$	
Profit for the period	Year ended March 31, 2016		Year ended March 31, 2017		Year ended March 31, 2017	
	¥	25,192	¥	56,036	\$	500,320
Other comprehensive income:						
Items that will not be reclassified to profit or loss:						
Net gain (loss) on financial assets measured at fair value through other comprehensive income		(1,411)		10,979		98,023
Remeasurement of defined benefit plans Share of net gain (loss) on financial assets		(3,261)		1,165		10,403
measured at fair value through other comprehensive income of investments in associates		(7)		0		0
		(4,679)		12,144		108,426
Items that may be reclassified subsequently to profit or loss:						
Exchange differences on translation of foreign operations		(360)		(96)		(859)
		(360)		(96)		(859)
Total other comprehensive income (loss)		(5,039)		12,048		107,567
Total comprehensive income for the period		20,153		68,083		607,888
Comprehensive income for the period attributable	to:					
Owners of the parent company		19,926		67,841		605,727
Non-controlling interests		227		242		2,160
Total comprehensive income for the period		20,153		68,083		607,888